Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2015 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

This presentation contains GAAP and certain non-GAAP financial measures. Non-GAAP financial measures are adjusted for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses and other specified items presented in AbbVie’s reconciliation tables. AbbVie’s management believes non-GAAP financial measures provide useful information to investors regarding AbbVie’s results of operations and assist management, analysts and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available in the appendix to this presentation and on the company’s website at [www.investors.abbvie.com](http://www.investors.abbvie.com).
Key Pipeline Events in 2017

Regulatory Approvals, Submissions & Registrational Study Milestones

**Regulatory Approvals**
- Imbruvica for 2L+ MZL ✓
- Imbruvica for 2L+ cGvHD
- G/P Next-Gen HCV

**Regulatory Submissions**
- Imbruvica for 2L+ cGvHD ✓
- Venclexta for r/r CLL
- Elagolix for endometriosis

**Phase 3 / Registrational Data Readouts**
- Upadacitinib (ABT-494) for rheumatoid arthritis
  - SELECT-NEXT in csDMARD-IR ✓
  - SELECT-BEYOND in bio-IR
  - SELECT-MONOTHERAPY in MTX-IR
- Risankizumab for psoriasis
  - ULTIMMA 1
  - ULTIMMA 2 vs. Stelara
  - IMMVENT vs. Humira
- Venclexta for r/r CLL (MURANO)*
- Imbruvica for 1L MCL (SHINE)*
- Rova-T for 3L+ SCLC (TRINITY)
- Depatux-m (ABT-414) for recurrent GBM
- Elagolix for endometriosis (final data w/ extension data)
- Elagolix for uterine fibroids

**Phase 3 / Registrational Study Starts**
- Upadacitinib (ABT-494) for Crohn’s disease
- Upadacitinib (ABT-494) for psoriatic arthritis ✓
- Upadacitinib (ABT-494) for axial SpA
- Risankizumab for Crohn’s disease
- Imbruvica + Venclexta for r/r MCL (SYMPATICO) ✓
- Venclexta for 1L AML w/ azacitidine ✓
- Venclexta for 1L AML w/ cytarabine
- Venclexta for 1L DLBCL w/ R-CHOP
- Rova-T for 1L SCLC (MERU) ✓
- Rova-T for 2L SCLC (TAHOE) ✓
- Elagolix for endometriosis (elagolix + hormonal add-back)

*Planned interim analysis; approximate dates as readouts are event driven
SELECT Phase 3 Program for Upadacitinib in Rheumatoid Arthritis

One of the most robust Phase 3 programs for RA
- 6 studies, nearly 4,800 patients, multiple patient types, 2 biologic comparators

<table>
<thead>
<tr>
<th>Patient Population</th>
<th>csDMARD-IR</th>
<th>MTX-naïve</th>
<th>MTX-IR</th>
<th>MTX-IR</th>
<th>Biologic-IR</th>
<th>Biologic-IR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scheme</td>
<td>Combo</td>
<td>Mono</td>
<td>Combo</td>
<td>Mono</td>
<td>Combo</td>
<td>Combo</td>
</tr>
<tr>
<td>Background</td>
<td>csDMARDs</td>
<td>MTX</td>
<td>csDMARDs</td>
<td>csDMARDs</td>
<td>abatacept</td>
<td>abatacept</td>
</tr>
<tr>
<td>Active Comparator</td>
<td>MTX</td>
<td>adalimumab</td>
<td>MTX</td>
<td></td>
<td>abatacept</td>
<td></td>
</tr>
<tr>
<td>Study Duration</td>
<td>12 weeks</td>
<td>48 weeks</td>
<td>48 weeks</td>
<td>14 weeks</td>
<td>24 weeks</td>
<td>24 weeks</td>
</tr>
<tr>
<td>Endpoints</td>
<td>Signs and Symptoms</td>
<td>Signs and Symptoms Structure</td>
<td>Signs and Symptoms Structure</td>
<td>Signs and Symptoms</td>
<td>Signs and Symptoms</td>
<td>Signs and Symptoms</td>
</tr>
<tr>
<td>Sample Size</td>
<td>661</td>
<td>975</td>
<td>1,500</td>
<td>600</td>
<td>450</td>
<td>550</td>
</tr>
</tbody>
</table>

On-track for regulatory submission in 2018 and commercialization in 2019
SELECT-NEXT Trial Demonstrates Compelling Data in csDMARD-IR Patients

<table>
<thead>
<tr>
<th>Patient Population</th>
<th>csDMARD-IR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scheme</td>
<td>Combo</td>
</tr>
<tr>
<td>Background</td>
<td>csDMARDs</td>
</tr>
<tr>
<td>Active Comparator</td>
<td>None</td>
</tr>
<tr>
<td>Study Duration</td>
<td>12 weeks</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Endpoints</th>
<th>Signs and Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample Size</td>
<td>661</td>
</tr>
</tbody>
</table>

- Safety profile was consistent with that observed in the upadacitinib Phase 2 clinical trials
- No new safety signals were detected
- Serious adverse events were 4 percent and 3 percent in the 15mg and 30mg dose arms, respectively, compared to 2 percent in placebo

*LDA and remission are by the DAS28 (CRP) criteria definitions
Detailed SELECT-NEXT results will be submitted for presentation at the ACR meeting in November
Key Efficacy Parameters in csDMARD-IR Studies for Selective JAK Inhibitors
- Placebo-adjusted week 12 results in Phase 3 studies

Upadacitinib 15mg QD
Upadacitinib 30mg QD
Baricitinib 2mg QD
Baricitinib 4mg QD

ACR20
ACR50
ACR70
LDA DAS28 (CRP)
Remission DAS28 (CRP)

Upadacitinib and baricitinib are investigational compounds under development by AbbVie and Eli Lilly, respectively. The data presented above are not from a head-to-head study; the data were derived from AbbVie’s SELECT-NEXT study and Eli Lilly’s RA-BUILD study. SELECT-NEXT was a Phase 3 study evaluating upadacitinib in patients with moderate to severe RA who had an inadequate response to treatment with csDMARDs. RA-BUILD was a Phase 3 study evaluating patients with moderate to severe RA who had an inadequate response to, or were intolerant of, at least one csDMARD and had not received a biologic DMARD. There are additional Phase 3 data for baricitinib not shown above, and additional Phase 3 studies for upadacitinib are ongoing.
**Upadacitinib Upcoming Milestone**

*Compelling data to-date; Significant potential across rheum, derm and gastro indications*

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th></th>
<th>2018</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1H</td>
<td>2H</td>
<td>1H</td>
<td>2H</td>
</tr>
<tr>
<td>RA</td>
<td>SELECT NEXT data</td>
<td>SELECT BEYOND data</td>
<td>SELECT MONO data</td>
<td>SELECT COMPARE data</td>
</tr>
<tr>
<td>RA</td>
<td>SELECT NEXT data</td>
<td>SELECT BEYOND data</td>
<td>SELECT MONO data</td>
<td>SELECT EARLY data</td>
</tr>
<tr>
<td>RA</td>
<td>Regulatory Submission in 2018</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**RA**
- **PsA**
  - Ph3 start

**AxSpA**
- Ph2b/3 start

**CD**
- Ph3 start

**UC**
- Ph2b data

**AD**
- Ph2 data
- Ph3 start
## Key Pipeline Events in 2017
### Regulatory Approvals, Submissions & Registrational Study Milestones

### Regulatory Approvals
- Imbruvica for 2L+ MZL
- Imbruvica for 2L+ cGvHD
- G/P Next-Gen HCV

### Regulatory Submissions
- Imbruvica for 2L+ cGvHD
- Venclexta for r/r CLL
- Elagolix for endometriosis

### Phase 3 / Registrational Data Readouts
- Upadacitinib (ABT-494) for rheumatoid arthritis
  - SELECT-NEXT in csDMARD-IR
  - SELECT-BEYOND in bio-IR
  - SELECT-MONOTHERAPY in MTX-IR
- Risankizumab for psoriasis
  - ULTIMMA 1
  - ULTIMMA 2 vs. Stelara
  - IMMVENT vs. Humira
- Venclexta for r/r CLL (MURANO)*
- Imbruvica for 1L MCL (SHINE)*
- Rova-T for 3L+ SCLC (TRINITY)
- Depatux-m (ABT-414) for recurrent GBM
- Elagolix for endometriosis (final data w/ extension data)
- Elagolix for uterine fibroids

### Phase 3 / Registrational Study Starts
- Upadacitinib (ABT-494) for Crohn’s disease
- Upadacitinib (ABT-494) for psoriatic arthritis
- Upadacitinib (ABT-494) for axial SpA
- Risankizumab for Crohn’s disease
- Imbruvica + Venclexta for r/r MCL (SYMPATICO)
- Venclexta for 1L AML w/ azacitidine
- Venclexta for 1L AML w/ cytarabine
- Venclexta for 1L DLBCL w/ R-CHOP
- Rova-T for 1L SCLC (MERU)
- Rova-T for 2L SCLC (TAHOE)
- Elagolix for endometriosis (elagolix + hormonal add-back)

*Planned interim analysis; approximate dates as readouts are event driven